When Columbus resident Jennifer Roberts’ family gets together for the holidays, they typically play a few games of bingo for ...

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. "Stronger ...

Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stronger liquidity will ensure our ...

Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...

Charlotte Proud, a Sunderland University apprentice born with Osteogenesis Imperfecta (Brittle Bone Disease), is determined ...

Charlotte Proud, 33, was diagnosed with Brittle Bone Disease - osteogenesis imperfecta - at just two years old, and has ...

Total operating expenses for the fourth quarter of 2024 were $287 million, including non-cash stock-based compensation of $40 ...

“My favorite movie is The Big Lebowski, the Unbreakable Boy second and then Zack Snyder’s Justice League. If I ever had to meet any actor, it would be Christian Bale. My favorite comedy actor, The ...

Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...